Myotonic

Quick links to important sections

Myotonic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myotonic

Quick Facts About Myotonic

Property Description
Active ingredient Methylergometrine (Methylergonovine)
Form Injection (Solution) and Tablet
Pharmacological class Oxytocic Agent / Ergot Alkaloid Derivative
General Purpose Promote uterine contraction and firmness
Origin Semi-synthetic

Understanding Myotonic's Identity

Myotonic is a prescription-only medication belonging to the pharmacological class known as Oxytocic Agents. Its sole active component is Methylergometrine, which is the official International Non-proprietary Name (INN) for the drug substance. Unlike some alternatives, Myotonic contains only this single active ingredient.

This medication is generally categorized as an Ergot Alkaloid Derivative, meaning its structure is chemically derived from components related to the natural ergot fungus, classifying it as a semi-synthetic compound. This single-ingredient medicine is available in two main physical forms: a solution for injection (for rapid effect) and as oral tablets, allowing for flexibility in how it is administered by healthcare professionals.


Role and Classification in Medicine

Myotonic's classification as an Oxytocic Agent defines its function: to stimulate and increase the tone and contraction of the smooth muscle in the uterus. As an oxytocic, Methylergometrine acts to induce sustained contraction of the uterus. This action is utilized for achieving uterine stability.

Unlike pure hormonal oxytocics, Methylergometrine provides a more sustained contractile effect due to its specific chemical structure as an ergot derivative. This sustained action is a key differentiating factor. The compound is classified among drugs used in specific obstetric care scenarios and acts to help the body control bleeding by tightening the target muscle.

This core purpose—helping to achieve and maintain uterine firmness—is the reason Myotonic is relied upon in clinical settings where muscle stability is essential.

What side effects are possible with Myotonic?

Possible Side Effects and Safety Information

The safety profile of Myotonic (Methylergometrine) is organized by regulatory agencies, classifying potential adverse reactions by frequency and the body system affected.

Adverse Reactions and Classification

Adverse events are primarily documented across the Vascular, Nervous System, and Cardiac system-organ classes, as defined in official prescribing information.

Common adverse reactions include Hypertension (high blood pressure), Hypotension (low blood pressure), Nausea, Vomiting, and Abdominal pain (resulting from uterine contractions). Less frequently observed are Rare reactions such as Acute myocardial infarction, various forms of Vasospasm, Bradycardia, Hallucinations, and Dizziness.

Serious Safety Considerations

Regulatory sources document rare but clinically significant adverse reactions, including Cerebrovascular accident, Seizure, and serious heart rhythm disturbances like Ventricular fibrillation. Severe hypersensitivity or Allergic Reactions are also noted in the safety summary.

Safety Restrictions and Special Populations

Use of Methylergometrine is contraindicated in conditions such as pre-existing Hypertension, Toxemia (pre-eclampsia, eclampsia), and hypersensitivity to ergot alkaloids. The medication should not be used during Pregnancy. Mothers should also not breast-feed during treatment and for a specific period after the last dose, as stated in the label. Caution is required in patients with pre-existing Cardiovascular Risk Factors or impaired renal/hepatic function, as they may be more susceptible to adverse effects. The standard regulatory framework strictly advises against routine intravenous administration due to the risk of sudden, severe hypertensive events.

Overdose and Emergency Response

Myotonic overdose may present with serious clinical manifestations across several physiological systems. Documented early signs include gastrointestinal effects such as nausea, vomiting, and abdominal pain. Neurological and sensory disturbances, including numbness and tingling (paresthesias) of the extremities, are also documented.

More severe outcomes involve the cardiovascular and central nervous systems. These include significant hypertension, which carries the risk of a cerebrovascular accident (stroke). Severe systemic effects listed in regulatory documents are convulsions (seizures), coma, and respiratory depression, alongside potential hypothermia.

Regulatory documents mandate that for any suspected overdose, immediate medical attention must be sought by contacting a poison control center or an emergency room at once. Urgent contact with emergency services is required if the person collapses, has a seizure, or experiences difficulty breathing or cannot be awakened.

General overdose management relies on supportive measures and drug clearance, as official prescribing information notes that no specific antidote is known. Documented procedures for supportive care include maintaining adequate pulmonary ventilation, controlling convulsions, correcting hypotension, and employing procedures such as gastric lavage. Inadvertent administration to a newborn is noted as an overdose of great magnitude for that population.

Therapeutic Uses of Myotonic

What Myotonic Treats: Main Uses and Benefits

Myotonic (Methylergometrine) is a medication generally used in specific obstetric and post-delivery clinical contexts, applied across domains where additional symptomatic support is needed. The therapeutic relevance of Myotonic is often discussed within standard obstetric care.

The medication is commonly used to help with the underlying conditions of uterine atony, postpartum hemorrhage, and uterine subinvolution. The core symptomatic benefit is the management of acute blood loss and support for muscle tone.

Managing Acute Bleeding and Flaccidity

This medication is relevant for managing the symptoms of excessive bleeding (hemorrhage) that may follow childbirth or an abortion procedure. The medication may assist with managing symptoms of acute blood loss, contributing to a more stable experience during these episodes. This supportive action is relevant when short-term symptomatic assistance is needed.

For conditions characterized by lack of muscle firmness (atony), its benefit lies in supporting the muscle to achieve necessary contractions required to stabilize the post-delivery state. This supportive action contributes to easing symptoms related to muscle flaccidity.


Quick Fact: Relief for Acute Blood Loss and Uterine Flaccidity

Myotonic is considered relevant in conditions presenting with acute or disruptive episodes of excessive bleeding and is applied in clinical settings that involve acute or unstable symptom patterns following delivery or obstetric procedures. It assists with maintaining functional stability during recovery.

Eligibility and Restrictions for Use

Who Can and Cannot Use Myotonic?

Eligibility for Myotonic (Methylergometrine) is strictly defined by regulatory authorities and is limited to specific adult populations under precise conditions.

Approved Population and Timing

Use is established for adult women in the postpartum period (following childbirth) or after an abortion. Official labeling explicitly mandates that the medicine must not be used during the first or second stages of labor, but only after the delivery of the anterior shoulder and the placenta.

Absolute Contraindications

Myotonic is contraindicated and must not be used in patients with several serious conditions, as defined in regulatory documentation:

  • Hypertension (high blood pressure).
  • Toxemia of pregnancy (including Preeclampsia and Eclampsia).
  • Vascular disease (e.g., coronary artery disease, peripheral vascular disease).
  • Known Hypersensitivity to methylergometrine or any excipient.
  • Existing Sepsis (severe infection).

Restricted Use and Ineligible Groups

Population Group Regulatory Status
Pediatric Patients Safety and effectiveness not established.
Impaired Liver/Kidney Function Use requires caution due to impaired drug metabolism/excretion.
Pregnancy (Antepartum) Contraindicated for use before delivery.
Breastfeeding/Lactation Not recommended; official documents advise discarding milk for at least 12 hours after use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Myotonic’s official interaction profile is characterized by its metabolism through the CYP 3A4 enzyme system and its classification as an ergot alkaloid. These two factors establish the regulatory constraints for co-administration.

Prohibited Combinations (Contraindicated) Co-administration of Myotonic with potent CYP 3A4 inhibitors is strictly prohibited. These drugs, which include certain azole antifungals (e.g., ketoconazole) and macrolide antibiotics (e.g., erythromycin), significantly reduce the clearance of Methylergometrine. This pharmacokinetic interaction increases plasma concentration, posing a severe risk of ergot toxicity and resulting vasospasm. The simultaneous use of other ergot alkaloids or Triptans is also contraindicated due to the high risk of severe, additive vasoconstrictive effects.

Interactions Requiring Caution

  • Pharmacodynamic Effects: Caution is warranted when co-administering with vasoconstrictors, sympathomimetics, or other oxytocic agents due to potential for additive effects (hypertension or increased uterotonic activity). The drug’s vasoconstrictive action is also expected to reduce the efficacy of antianginal drugs.
  • Dietary and Population Notes: Co-consumption of Grapefruit Juice is officially not advised as it acts as a less potent CYP 3A4 inhibitor. Caution is also warranted for patients with hepatic or renal impairment, as slower elimination in these populations may increase drug exposure.

Mechanism of Action

How Myotonic Works

Myotonic acts through a dual-pathway mechanism focusing on molecular defects and resulting cellular dysregulation. The primary action involves engaging mechanisms that reduce the concentration of abnormal, expanded CUG/CCUG repeat RNA, which constitutes a toxic RNA gain-of-function.

Modulation of Toxic RNA and Alternative Splicing

The molecule initiates a process that promotes the dissociation of inhibitory complexes involving the toxic RNA and RNA-binding proteins, such as MBNL1 (Muscleblind-like 1). This interaction modifies early molecular steps within the cell, altering the alternative splicing profile of numerous downstream pre-mRNAs. This cascade influences systemic physiological outcomes by regulating overactive or dysregulated processes at the genetic level.

Influence on Muscle Membrane Excitability

Secondary effects include the adjustment of pathways regulating muscle membrane excitability. Specifically, the drug alters the splicing of the messenger RNA for the chloride channel 1 (ClC-1). This modulation alters chloride conductance across the muscle cell membrane. This results in physiological adjustments that influence the electrical parameters of the muscle, affecting both the contraction and relaxation phases.

Dosage and Administration Information

How Myotonic (Methylergometrine) Is Used

Myotonic (Methylergometrine) is administered through dual routes and forms that correspond to the phase of clinical need. The medication is supplied as a 0.2 mg injectable solution for acute intervention and as a 0.2 mg oral tablet for subsequent short-term maintenance.

Administration Routes and Dosing The initial dose of 0.2 mg is most commonly given via intramuscular (IM) injection following the delivery process. This parenteral dose can be repeated as necessary, typically at intervals of 2 to 4 hours, for acute phase management. For maintenance, the regimen transitions to the oral tablet (0.2 mg), generally taken three or four times daily. The use of the oral tablets is restricted to a maximum duration of one week postpartum.

Procedural Constraints While IM injection is the routine parenteral option, administration via the intravenous (IV) route is strictly reserved for emergency situations. When IV use is essential, the injection must be given slowly over a period of no less than 60 seconds with mandated close blood pressure monitoring. Routine IV use is advised against, and the parenteral solution must be visually inspected for any discoloration or particulate matter prior to use. For specific populations, the safety of the drug has not been established for pediatric use, and conservative dosing is noted for patients with hepatic or renal impairment.

Recent Clinical Evidence

Evidence for the Management of Postpartum Bleeding and Uterine Tone

Research has primarily involved Myotonic (Methylergometrine) in clinical situations associated with postpartum hemorrhage (PPH), which is often linked to uterine atony—a condition where the muscle lacks firmness after delivery. Trials exploring this area include numerous Randomized Controlled Trials (RCTs) and systematic reviews. Myotonic was evaluated in these studies, which focused on both the prevention and active research contexts involving excessive bleeding associated with uterine atony.

In these trials, studies explored outcomes describing episodic or acute changes. Research highlights changes measured during the study period, with findings often reporting measurements of the actual volume of blood loss collected from the patient. Studies also explored outcomes reflecting the requirement for further medical attention, such as an immediate blood transfusion or the administration of other supportive medications.

  • How Trials Measured Study Outcomes

Researchers recorded the level of tone or firmness in the uterine muscle using standardized clinical scoring systems. Findings also indicate how systemic balance was observed, with studies reporting measurements related to the patients' hemoglobin and hematocrit levels—markers that reflect blood status. These measurements describe group patterns, not personal outcomes, and research provides context but not individual predictions.


Research on Duration of Effect and Follow-Up Periods

Research exploring short-term symptom changes has concentrated heavily on the immediate postpartum period. Follow-up durations were limited in most primary efficacy trials. While evidence describes patterns observed in the immediate post-delivery setting, there is limited information for long-term outcomes related to durability or extended effects. Some studies did continue to monitor patients into the early puerperium, sometimes extending up to approximately 10 days post-delivery.


What Is Still Uncertain About the Research for Myotonic

Evidence highlights what is known and what is still uncertain regarding the research landscape. One area of uncertainty relates to its findings when studied in comparison in head-to-head trials against other uterotonic agents used for the same purpose, where the data show mixed patterns across various studies. Furthermore, research findings are uncertain, and data are still emerging for its use in patients who have severe kidney or liver impairment, as evidence is limited for these specific comorbid conditions.

Key Studies & References

  1. Postpartum hemorrhage: summary of the 2017 ACOG practice bulletin

Frequently Asked Questions (FAQ)

Common questions about Myotonic (FAQ)

Q: How long does the effect of a Myotonic dose typically last?

The onset and duration of effect are tied to how the medicine is administered. According to official product information, the active ingredient's highest concentration in the bloodstream is typically reached about 30 minutes to 2 hours after taking an oral dose. The prescribing information outlines the medication's use for short-term maintenance.


Q: Are there any common over-the-counter medicines that interact with Myotonic?

Official guidance on drug interactions advises caution with certain over-the-counter (OTC) medicines. Specifically, OTC products containing ingredients classified as vasoconstrictors or sympathomimetics should be noted, as these may have additive effects with Myotonic. The official label recommends informing a healthcare provider about all medicines being taken.


Q: How does Myotonic affect the liver or kidneys?

Myotonic is primarily eliminated from the body by the liver and kidneys. Caution is warranted for patients who already have impaired function in these organs, as slower elimination may increase the concentration of the medicine in the body. This is a key safety consideration noted in official documents.


Q: What does it mean that Myotonic has a 'Boxed Warning'?

A Boxed Warning is the highest safety alert placed on a prescription drug’s official labeling, used to highlight serious or potentially life-threatening risks. For Myotonic, the warning relates to the risk of severe, sudden high blood pressure (hypertension) and constricted blood vessels (vasospasm) when the injectable form is administered into a vein (IV).


Q: What is the average time before I can expect to see the full benefits of Myotonic?

Official information indicates that the medicine acts quickly due to its intended use in acute clinical settings. For the injectable form, the therapeutic effect typically begins within 2 to 5 minutes. The oral form's effect is generally observed within 5 to 10 minutes after administration.


Q: Do I need to avoid driving or operating machinery while taking Myotonic?

The active ingredient has been associated with nervous system side effects, including dizziness and, rarely, hallucinations. Because of the potential for impaired judgment or attention, regulatory documents advise that activities requiring mental alertness, such as driving or operating machinery, may be impaired.


Q: What do patients commonly misunderstand about how Myotonic works?

The mechanism of Myotonic involves both the action of an Oxytocic Agent (to promote uterine firmness) and complex molecular processes. The molecular effects described in the label include action on the toxic RNA pathway and the chloride channel within muscle cells. This dual description may require clarification to emphasize that the main approved clinical purpose is to achieve uterine stability.


Q: What happens if I forget to take Myotonic at the usual time?

If a dose of the oral tablet is missed, official patient instructions typically state not to attempt to catch up by doubling the next dose. Instead, the next dose should be taken at its regularly scheduled time.


Q: Can vitamins or herbal supplements cause problems if taken with Myotonic?

Official documents advise caution regarding certain herbal supplements. Specifically, supplements that are known to inhibit the CYP 3A4 enzyme may increase the risk of adverse reactions, as they slow down the medicine's breakdown in the body. Grapefruit juice is also officially not advised as it acts as a less potent inhibitor.


Q: Is tiredness or drowsiness a common side effect of Myotonic?

Regulatory documents list a range of nervous system effects, including dizziness and headache. While not classified as a common side effect, fatigue and various sleep disorders have been reported in post-marketing summaries.


Q: Does taking Myotonic require regular blood tests or monitoring?

Close monitoring of blood pressure is mandated by regulatory documents when the injectable form is administered. Routine laboratory blood testing, such as comprehensive blood panels or liver/kidney tests, is not specified as a standard requirement for all patients taking the oral tablets.


Q: Is Myotonic a controlled substance?

Official scheduling information indicates that the active ingredient, Methylergometrine, is not classified as a federally controlled substance in the U.S. or Canada. It is legally classified as a prescription-only medicine.


Q: Can people develop a dependence on Myotonic?

According to regulatory documents, the active ingredient in Myotonic has not been categorized as having a potential for abuse or the development of dependence.


Q: Is it possible for Myotonic to affect my mood or sleep?

Regulatory information lists both hallucinations and various sleep disorders (such as insomnia) among the nervous system adverse reactions that have been reported. These effects indicate that the medicine has the potential to affect mood or sleep patterns.


Q: Is Myotonic a new drug, or has it been available for a long time?

The active ingredient, Methylergometrine, is not considered a new medication. It has been approved and utilized as a prescription medicine for promoting uterine firmness for several decades.


Q: Does Myotonic have a generic version available?

Regulatory records show that the active ingredient, Methylergometrine, is produced by various manufacturers and is available under both the brand name Myotonic and as a generic product.


Q: What should I do if I accidentally take too much Myotonic?

Official information states that in cases of potential overdose, immediate medical attention is required. Signs of acute overdosage described in regulatory documents include severe digestive issues like nausea and vomiting, stomach pain, and rapid changes in blood pressure.


Q: Is it normal to feel a tingling sensation when starting Myotonic?

A tingling sensation, known medically as paresthesia, is noted in official documents among the less common nervous system side effects reported. The official labeling lists this as a possible adverse reaction.


Q: What kind of specialist usually prescribes Myotonic?

Myotonic is approved for use after childbirth or abortion, which falls within the scope of obstetric care. Therefore, the medication is typically prescribed by specialists or physicians involved in labor, delivery, and immediate postpartum management.


Q: What is the purpose of the inactive ingredients in Myotonic tablets?

The inactive ingredients, also called excipients, serve functional purposes in the tablet formulation. These components ensure the proper release of the active medicine, preserve its stability over time, and help maintain the physical structure of the tablet.

How should Myotonic be stored and disposed of?

Storage and Disposal Requirements

The official storage requirements for Myotonic (Methylergometrine) differ by dosage form, and all forms must be stored out of the reach of children.


Official Storage Conditions

Dosage Form Temperature Requirement Handling and Protection
Oral Tablets Controlled Room Temperature (20 C to 25 C) Store in a tightly closed, light-resistant container, protected from moisture and excess heat.
Injection Refrigeration (2 C to 8 C) Do not freeze; must be protected from light. Store separately from medications intended for newborns.

Disposal Instructions

Unused or expired Myotonic should be discarded through a medicine take-back program. It must not be disposed of by flushing it down the toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Myotonic found in:

A-Z Index: